RSV vaccines prove effective as US tightens access restrictions
New data reinforce that RSV vaccines dramatically reduce hospitalizations, with pregnancy-based protection around 70% and newborn monoclonal antibodies about 81%, and four JAMA studies confirm declines. Despite this, the administration’s restrictions to high‑risk infants could raise RSV hospitalizations and complicate vaccine logistics in a fragmented US system. Safety reviews are underway after trial deaths, though officials say there’s no proven vaccine link, and many countries rely on universal prenatal vaccination.
